Login
Aktis Oncology, Inc. logo

Aktis Oncology, Inc.

Compare classes
aktisoncology.com

What Do They Do?

Develops miniprotein radioconjugate drug candidates that deliver radioactive medicines to solid tumors for cancer patients.

Who Are Their Customers?

Eli Lilly works directly with Aktis under a strategic collaboration to develop radioconjugates outside Aktis’ proprietary pipeline.

How Are They Changing?

Since the latest annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +147%
vs $1.6M in Q3 FY2025
Net income
▼ −93% (Loss)
vs −$15.5M in Q3 FY2025

Who Do They Compete With?

Competes with Abdera Therapeutics, Actinium Pharmaceuticals, Alpha9 Oncology, Artbio, Bayer, Convergent Therapeutics, Fusion Pharmaceuticals, Johnson & Johnson, Mariana Oncology, Perspective Therapeutics, POINT Biopharma Global, RadioMedix, Radionetics Oncology, RayzeBio, Telix Pharmaceuticals, Lantheus Holdings, Novartis, Sirtex, Boston Scientific, and Q BioMed

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support